Stress Urinary Incontinence
Conditions
Keywords
Postmenopausal women
Brief summary
The overall objective of this study is to establish if testosterone replacement in post-menopausal women with low testosterone levels and stress urinary incontinence (SUI) will lead to improvement in symptoms of SUI. This study is a prospective, randomized, double-blind, placebo-controlled, parallel-group, clinical trial and will involve sixty (60) post-menopausal women with clinically diagnosed stress urinary incontinence and low testosterone concentrations. These subjects will enter the control period, which involves the baseline measurements of pelvic floor muscle volume and strength, amounts of urine leakage in 24-hour period, urodynamic parameters, and quality of life using Incontinence Impact Questionnaire and Urogenital Distress Inventory. Subjects are then randomly assigned to either placebo (30 subjects) or 300 mcg/twice-weekly testosterone patch (30 subjects) group. Both the subjects and investigators will be blinded. The duration of the testosterone/control study will be 36 weeks, with weeks 1-3 screening/control period, 4-28 application of placebo or testosterone patches and 29-36 recovery time/assessment of effects.
Detailed description
Primary Outcome Measure: Our primary outcome measure is the change in levator ani muscle volume with correlation in improvement in stress incontinence. These will be assessed by MRI, urodynamic studies and pad tests. \[Time Frame: 36 weeks\] Secondary Outcome Measures: Our secondary outcome measures are: \[Time Frame: 36 weeks\] 1. Change in urodynamic measurements including urethral pressure profile, cough stress profile, maximum urethral closure pressure, Valsalva leak point pressure, and pressure transmission ratios. 2. Change in pelvic floor muscle strength as measured with a perineometer. 3. Change in amounts of urinary leakage (in a 24 hour period) using the Pad Test. 4. Change in subjective quality of life as it relates to incontinence using the Incontinence Impact Questionnaire, Urogenital Distress Inventory and Incontinence Diary. 5. Change in hormone levels including total and free testosterone, dihydrotestosterone (DHT), estradiol 17 B, and sex hormone binding globulin (SHBG). 6. Change in complete blood count, chem 20, lipid profile (total cholesterol, triglyceride, HDL, LDL) and physical examination as compared to the baseline before treatment.
Interventions
DRUGTestosterone patch
300 mcg testosterone patches or placebo applied twice weekly
DRUGPlacebo
Placebo patch
Sponsors
Charles Drew University of Medicine and Science
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
45 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Inclusion Criteria: * Ambulatory, postmenopausal women * The presence of stress urinary incontinence, defined as involuntary urine loss during physical activity, cough, or sneeze. * Able to understand and give informed consent. * Those on estrogen replacement therapy prior to the study should have been on a stable regimen for at least three months. For those who are not on estrogen replacement therapy prior to the study, will not be started on estrogen for the duration of the study. * Normal Pap smear and mammogram in the preceding 12 months by history and chart review.
Exclusion criteria
* Uncontrolled depression as assessed by history and physical exam. * Those with any acute or chronic illness, malignant disease, fever of known or unknown origin, diabetes mellitus (fasting blood glucose \> 126 mg/dl), or uncontrolled hypertension (defined as blood pressure greater than 160/100). * Current urinary tract infection (UTI). For those with acute UTI, treatment will be given and repeat culture should be negative before enrollment. * Severe obesity defined as body mass index of greater than 40 kg/m2. * Current or recent (last 6 months) use of illicit drugs (which may affect appetite, food intake, metabolism, and/or compliance with the protocol). * Current or recent (last 6 months) alcohol or drug dependence. * Significant liver function abnormalities defined as AST, ALT, or alkaline phosphatase value of greater than three times the upper limit of normal in our Clinical Pathology Laboratory, or serum bilirubin levels of greater than 2 mg/dl. * History of breast or endometrial cancer. * History of hyperandrogenic disorders such as hirsutism and polycystic ovary disease. * Previous intolerance to testosterone. * Women with abnormal PAP smears or mammograms will be included only after they have been evaluated by their gynecologists and breast and uterine/cervical cancers have been excluded by appropriate diagnostic tests. * Women with significant dementia as assessed by history and physical exam. * Those with disabilities that would prevent them from participating in the outcome testing, including tests of pelvic floor strength (e.g. severe arthritis, Parkinson's disease, stroke, or myopathy). * Those who have received in the preceding three months drugs known to affect testosterone production or metabolism such as Ketoconazole, Megace, and or anabolic/androgenic steroids. * Because of their age and post-menopausal status, spontaneous pregnancy is unlikely. Regardless, women who are pregnant, seeking to become pregnant in the next six months, or breastfeeding will not be included. * Subjects who cannot have an MRI due to metal implants or pacemaker.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Our primary outcome measure is the change in levator ani muscle volume with correlation in improvement in stress incontinence. | 36 weeks | This outcome will be assessed by MRI, urodynamic studies and pad tests. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in pelvic floor muscle strength. | 36 weeks | This outcome will be measured with a perineometer. |
| Change in amounts of urinary leakage. | 36 weeks | This will be measured with the Pad Test ( in a 24 hour period). |
| Change in urethral pressure profile. | 36 weeks | This outcome will be evaluated with urodynamic measurement of urethral pressure (in cm H2O) along the urethra. |
| Change in hormone levels including total and free testosterone, dihydrotestosterone (DHT), estradiol 17 B, sex hormone binding globulin (SHBG). | 36 weeks | These will be measured at the baseline (before treatment) and then every four weeks during the treatment and recovery periods and compared with the baseline. |
| Change in laboratory values. | 36 weeks | The blood sample will be collected for laboratory measurement (CBC, chem 20, lipid profile) at the baseline (before treatment) and then every four weeks during the treatment and recovery periods and compared with the baseline. |
| Change in subjective quality of life as it relates to incontinence. | 36 weeks | This outcome will be measured with a validated questionnaire and compared with the baseline before treatment. |
Countries
United States
Outcome results
None listed